发明名称 |
Crystalline form of a quinolinone-carboxamide compound |
摘要 |
The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing such crystalline salt forms. |
申请公布号 |
US9402840(B2) |
申请公布日期 |
2016.08.02 |
申请号 |
US201514816237 |
申请日期 |
2015.08.03 |
申请人 |
Theravance Biopharma R&D IP, LLC |
发明人 |
Fatheree Paul R.;Turner S. Derek;Goldblum Adam A.;Chao Robert S.;Genov Daniel |
分类号 |
A61K31/46;C07D451/02 |
主分类号 |
A61K31/46 |
代理机构 |
|
代理人 |
Hagenah Jeffrey A.;Saxon Roberta P. |
主权项 |
1. A method of treating a disorder of reduced motility of the gastrointestinal tract in a mammal, wherein the disorder of reduced motility is chronic constipation, constipation-predominant irritable bowel syndrome, gastroparesis, drug-induced delayed transit, or functional dyspepsia, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutical carrier and a crystalline hydrate of the hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide which is characterized by a thermal gravimetric analysis trace substantially in accordance with the bottom trace in FIG. 5 and by a powder x-ray diffraction pattern having diffraction peaks at 2θ values of 10.52±0.2, 13.85±0.2, 15.80±0.2, 17.26±0.2, and 21.06±0.2. |
地址 |
South San Francisco CA US |